WO2003045978A3 - Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment - Google Patents

Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment Download PDF

Info

Publication number
WO2003045978A3
WO2003045978A3 PCT/US2002/038164 US0238164W WO03045978A3 WO 2003045978 A3 WO2003045978 A3 WO 2003045978A3 US 0238164 W US0238164 W US 0238164W WO 03045978 A3 WO03045978 A3 WO 03045978A3
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibody
multiple sclerosis
antibody therapy
antagonist anti
sclerosis treatment
Prior art date
Application number
PCT/US2002/038164
Other languages
French (fr)
Other versions
WO2003045978A2 (en
Inventor
Lorianne K Masuoka
Min F Kwan
Original Assignee
Chiron Corp
Lorianne K Masuoka
Min F Kwan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Lorianne K Masuoka, Min F Kwan filed Critical Chiron Corp
Priority to AU2002346581A priority Critical patent/AU2002346581A1/en
Priority to JP2003547427A priority patent/JP2005510570A/en
Priority to EP02784651A priority patent/EP1455812A4/en
Priority to CA002466931A priority patent/CA2466931A1/en
Publication of WO2003045978A2 publication Critical patent/WO2003045978A2/en
Publication of WO2003045978A3 publication Critical patent/WO2003045978A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention is directed to a method for preventing or alleviating the symptons of MS by delivering to the central nervous system an interferon and an anti-CD40 antibody. Interferons include interferon-β and its muteins such as IFN-βser17.
PCT/US2002/038164 2001-11-26 2002-11-26 Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment WO2003045978A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2002346581A AU2002346581A1 (en) 2001-11-26 2002-11-26 Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
JP2003547427A JP2005510570A (en) 2001-11-26 2002-11-26 Antagonist anti-CD40 monoclonal antibody therapy for treatment of multiple sclerosis
EP02784651A EP1455812A4 (en) 2001-11-26 2002-11-26 Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
CA002466931A CA2466931A1 (en) 2001-11-26 2002-11-26 Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33335501P 2001-11-26 2001-11-26
US60/333,355 2001-11-26

Publications (2)

Publication Number Publication Date
WO2003045978A2 WO2003045978A2 (en) 2003-06-05
WO2003045978A3 true WO2003045978A3 (en) 2003-07-31

Family

ID=23302439

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/038164 WO2003045978A2 (en) 2001-11-26 2002-11-26 Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment

Country Status (5)

Country Link
EP (1) EP1455812A4 (en)
JP (1) JP2005510570A (en)
AU (1) AU2002346581A1 (en)
CA (1) CA2466931A1 (en)
WO (1) WO2003045978A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102585011A (en) * 2012-02-10 2012-07-18 中国农业大学 Preparation method for dog alpha interferon derivative and application
US8828396B2 (en) 2010-11-15 2014-09-09 Novartis Ag Silent Fc variants of anti-CD40 antibodies

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
DK1682178T3 (en) * 2003-11-04 2010-10-04 Novartis Vaccines & Diagnostic Methods for therapy of cancers expressing the CD-40 antigen
EP1945260B1 (en) 2005-11-01 2012-10-24 Novartis AG Uses of anti-cd40 antibodies
GEP20125628B (en) 2006-04-21 2012-09-10 Novartis Ag Pharmaceutical compositions containing antagonist anti-cd40 antibody
GB0707208D0 (en) * 2007-04-13 2007-05-23 Istituto Superiore Di Sanito Novel disease treatments
US20210251994A1 (en) 2018-06-15 2021-08-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
JP2021169423A (en) * 2020-04-15 2021-10-28 洋悦 松川 Method for administering pharmaceutical preparation
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
KR20230157315A (en) 2021-01-28 2023-11-16 리제너론 파마슈티칼스 인코포레이티드 Compositions and methods for treating cytokine release syndrome

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060450A (en) * 1995-03-16 2000-05-09 University Of Florida Method for treatment of autoimmune diseases
US6312693B1 (en) * 1998-02-19 2001-11-06 Alejandro A. Aruffo Antibodies against human CD40
WO2001083755A2 (en) * 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060450A (en) * 1995-03-16 2000-05-09 University Of Florida Method for treatment of autoimmune diseases
US6312693B1 (en) * 1998-02-19 2001-11-06 Alejandro A. Aruffo Antibodies against human CD40
WO2001083755A2 (en) * 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1455812A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8828396B2 (en) 2010-11-15 2014-09-09 Novartis Ag Silent Fc variants of anti-CD40 antibodies
CN102585011A (en) * 2012-02-10 2012-07-18 中国农业大学 Preparation method for dog alpha interferon derivative and application

Also Published As

Publication number Publication date
AU2002346581A8 (en) 2003-06-10
WO2003045978A2 (en) 2003-06-05
JP2005510570A (en) 2005-04-21
AU2002346581A1 (en) 2003-06-10
EP1455812A2 (en) 2004-09-15
CA2466931A1 (en) 2003-06-05
EP1455812A4 (en) 2006-03-22

Similar Documents

Publication Publication Date Title
WO2003045978A3 (en) Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
IL146950A0 (en) Recombinant anti-cd40 antibody and uses thereof
AU2002322478A1 (en) Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
PL366694A1 (en) Methods of administering anti-tnfalpha antibodies
AU2002327378A1 (en) Treatment of neuropsychiatric disorders by near-diaphragmatic nerve stimulation
DK0814831T3 (en) Medications to treat autoimmune diseases using interferon tau
WO2005000194A3 (en) Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
WO2006036371A3 (en) Combination therapy
WO2003037886A3 (en) Heteroaromatic carboxamide derivatives for the treatment of inflammation
TW200505416A (en) Bi-aryl compound having immunosuppressive activity
WO2003062241A8 (en) Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function
AU2003285091A8 (en) Interferon antagonists useful for the treatment of interferon related diseases
EP1135477A4 (en) Humanized monoclonal antibodies
WO2003049705A3 (en) Use of pramipexole to treat amyotrophic lateral sclerosis
WO2002085405A3 (en) COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF$g(a)
WO1999059617A3 (en) Immunoregulator
PL373565A1 (en) Methods and compositions for treatment of immune dysfunction disorders
WO2005011605A3 (en) Combination therapies for multiple sclerosis
WO2005123113A3 (en) Interferon compositions and methods of use thereof
WO2001017537A3 (en) Methods and compositions for reducing immune response
IL153557A0 (en) Antibodies and antagonists to antimicrobial peptides for the purpose of treating, inhibiting and preventing auto immune diseases
AU2002304931A1 (en) Methods for treating disorders of the nervous and reproductive systems
WO2002022079A3 (en) Methods of preparing immune globulin and uses thereof
UA83989C2 (en) Isolated peptide for promoting anti-tumor immune response, pharmaceutical composition based thereon and use thereof
WO2003097082A3 (en) Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2466931

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003547427

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002784651

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002784651

Country of ref document: EP